Floatz logo

Nuv-868

Cancer of Prostate

Nuvation Bio Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

114 Active assets in the Cancer of Prostate cohort.

Asset / SponsorPhaseRating
LEUPROLIDE
Mayo Clinic
Phase 4BBB
Degarelix
Baptist Health South Florida
Phase 3BBB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Enzalutamide
Pfizer
Phase 4BBB
Abiraterone Acetate
Mayo Clinic
Phase 4BBB

View all 50 →

Same molecule, other indications

Nuv-868 is also rated in:

prostate neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
ovarian neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
castration-resistant prostate carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →